Robert Fine, M.D.
Administrative Office Tel - 212 305-1168
Fax - 212 305-7348
Outpatients Office Location
Irving Pavilion 10
161 Fort Washington Ave at W 165th St.
Robert L. Fine, M.D., is the Herbert Irving Associate Professor of Medicine and Director of Experimental Therapeutics at the Herbert Irving Comprehensive Cancer Center, New York Presbyterian Hospital-Columbia University Medical Center. Dr. Fine specializes in caring for patients with pancreatic cancer, neuroendocrine cancers, untreatable tumors and brain tumors. His expertise lies in creating new experimental therapies for his laboratory and translating them directly to the clinic population. Dr. Fine received his B.A. and B.S. degrees in Philosophy and BioChemistry and finished medical school at the University of Chicago Pritzker School of Medicine where he graduated with research honors. He conducted his internal medicine training at Stanford University Hospital and did a medical oncology fellowship at the National Cancer Institute, National Institutes of Health, where he stayed on faculty for an additional three years in experimental pharmacology. He then spent six years at Duke University Cancer Center as an Assistant Professor of Medicine before coming to Columbia in 1996.
Dr. Fine is involved in clinical and experimental research in the following solid tumors: pancreatic cancer, neuroendocrine cancers, untreatable tumors and brain tumors. He currently runs seven investigator-initiated clinical trials in GI and neuroendocrine tumor studies. In addition, his laboratory with three Ph.D. postdoctoral fellows have developed a new gene therapy for pancreatic cancer and a P53 peptide therapy for mutant P53 cancers, which have been patented and hold great promise as new treatments for cancer. Additionally, he has developed two separate novel treatments for pancreatic cancer that are currently being tested in the clinic. Preliminary results for the GTX study show higher response and survival rates than any other study published as well as the highest successful conversion rate of inoperable pancreatic cancer into operable status. He has published 105 peer-reviewed articles, 220 abstracts, and 18 book chapters. Recently, Dr. Fine was chosen by his peers as one of the top three thought leaders in pancreatic cancer, and has been listed for the past three years in New York Magazine as one of the top doctors in his field.
- Gastrointestinal Cancers
- Pancreatic Cancer
- Internal Medicine
- Associate Professor of Medicine, Columbia University Medical Center
- B.S., 1975, The Richard Stockton College of New Jersey, Pomona, NJ
- M.D., 1979, University of Chicago, Pritzker School of Medicine, Chicago, IL
Internship and Residency
- Internal Medicine, 1982, Stanford University Hospital, Stanford, CA
- Oncology, 1985, Medicine Branch, National Cancer Institute, NIH, Bethesda, MD